Anti-Gp210 and Anti-Sp100 Antibody Status and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis

Abstract

with poorer clinical outcomes, and possibly with non-response to ursodeoxycholic acid. We aimed to analyze the association between these primary biliary cholangitis-specific antinuclear antibodies, anti-gp210 and anti-sp100, and ursodeoxycholic acid response in primary biliary cholangitis. MATERIAL AND METHODS: A retrospective audit was performed on 92 patients with primary biliary cholangitis for whom specific antinuclear antibody status and ursodeoxycholic acid response data was available. The response to ursodeoxycholic acid, assessed using Barcelona and Paris II criteria, was analyzed according to anti-gp210 and/or anti-sp100 positivity. RESULTS: There was a non-significantly lower ursodeoxycholic acid response rate among anti-gp210 positive patients (12/18, 66.7%) compared with anti-gp210 negative patients (57/74, 77.0%, p = 0.5439); and in anti-sp100 positive patients (15/21, 71.4%) compared with anti-sp100 negative patients (54/71, 76.1%, p = 0.886). On univariate analysis and multivariate analysis, there was no significant change in odds of ursodeoxycholic acid response with either anti-gp210 or anti-sp100 positivity. CONCLUSION: This study found that there was no association between anti-gp210 or anti-sp100 antibody status and response to ursodeoxycholic acid in a European primary biliary cholangitis cohort. This is in contrast to previous literature. However there was a trend towards an association between primary biliary cholangitis-specific antinuclear antibody positivity and lower ursodeoxycholic acid response rates. Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http: //creativecommons.org/licenses/by-nc/4.0/ ABSTRACT AIMS: Primary biliary cholangitis is a chronic biliary liver disease, for which the prognosis is poorer in patients who do not respond satisfactorily to the mainstay of treatment, ursodeoxycholic acid. Evidence suggests the presence of primary biliary cholangitis specific antinuclear antibodies such as anti-gp210 or anti-sp100 are associated